Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.79
- Piotroski Score 3.00
- Grade Neutral
- Symbol (ALLR)
- Company Allarity Therapeutics, Inc.
- Price $1.75
- Changes Percentage (2.34%)
- Change $0.04
- Day Low $1.69
- Day High $1.80
- Year High $666.00
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2,043.41
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-11,901,000
Income Statement
Quarterly
Annual
Latest News of ALLR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Father of Marine veteran once held captive by Russia discusses his Texas Senate race endorsement of Colin Allred over Ted Cruz
Joey Reed chose to endorse Colin Allred over Ted Cruz for U.S. Senate due to Cruz's lack of assistance when Reed's son was detained in Russia. Reed criticized Cruz for not helping, while Allred's supp...
By CBS News | 16 hours ago -
Democrats invest new money into Allred campaign as Texas Senate race against Cruz becomes more competitive
Senate Democrats are investing millions in Colin Allred's campaign against Ted Cruz. The race is tightening. Also, upcoming VP debate and State Fair of Texas gun ban upheld by Texas Supreme Court....
By CBS News | 6 days ago -
Investors in Allreal Holding (VTX:ALLN) have seen returns of 2.0% over the past five years
To assess the performance of individual stocks, comparing it with a market index fund is crucial. Despite Allreal Holding AG's stock decline of 16% over five years, its total shareholder return (TSR) ...
By Yahoo! Finance | 6 days ago